A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Clinical trial NCT03535740 · COMPLETED
Trial details
- NCT number
- NCT03535740
- Sponsor
- Ariad Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2020-09-30
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.